U.S. Insurance Outlook 2012: Finding The Right Strategy In A Volatile Environment Nov 11

  • ID: 2038923
  • November 2011
  • Region: United States
  • Standard & Poors
1 of 2

The U.S. insurance industry will face challenges in 2012 springing largely from the enervated state of the national economy. Standard & Poor's Ratings Services believes that the odds of another recession in 2012 remain at 35%--not a sign of a robust economy to be sure, but better than even money that the economy will continue to grow, even if only slowly. But slow growth, high unemployment, low interest rates, a volatile political roadmap, and uncertain fiscal policy outcomes in Europe and the U.S. mean that insurers will need to be as mindful of potential headwinds and as nimble in responding to them as at any time since the worst of the recent credit crisis. Our outlooks on the biggest insurance...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.